Impact of HPV Vaccination and Cervical Screening on Cervical Cancer Elimination: A Comparative Modelling Analysis in 78 Low-income and Lower-middle-income Countries

Background
The WHO Director-General has issued a call for action to eliminate cervical cancer as a public health problem. To help inform global efforts, we modelled potential human papillomavirus (HPV) vaccination and cervical screening scenarios in low-income and lower-middle-income countries (LMICs) to examine the feasibility and timing of elimination at different thresholds, and to estimate the number of cervical cancer cases averted on the path to elimination.

Findings
Girls-only HPV vaccination was predicted to reduce the median age-standardized cervical cancer incidence in LMICs from 19·8 (range 19·4–19·8) to 2·1 (2·0–2·6) cases per 100 000 women-years over the next century (89·4% [86·2–90·1] reduction), and to avert 61·0 million (60·5–63·0) cases during this period. Adding twice-lifetime screening reduced the incidence to 0·7 (0·6–1·6) cases per 100 000 women-years (96·7% [91·3–96·7] reduction) and averted an extra 12·1 million (9·5–13·7) cases. Girls-only vaccination was predicted to result in elimination in 60% (58–65) of LMICs based on the threshold of four or fewer cases per 100 000 women-years, in 99% (89–100) of LMICs based on the threshold of ten or fewer cases per 100 000 women-years, and in 87% (37–99) of LMICs based on the 85% or greater reduction threshold. When adding twice-lifetime screening, 100% (71–100) of LMICs reached elimination for all three thresholds. In regions in which all countries can achieve cervical cancer elimination with girls-only vaccination, elimination could occur between 2059 and 2102, depending on the threshold and region. Introducing twice-lifetime screening accelerated elimination by 11–31 years. Long-term vaccine protection was required for elimination.

Interpretation
Predictions were consistent across our three models and suggest that high HPV vaccination coverage of girls can lead to cervical cancer elimination in most LMICs by the end of the century. Screening with high uptake will expedite reductions and will be necessary to eliminate cervical cancer in countries with the highest burden.

Read the full article in The Lancet.

You May Also Like

Scoping Review of Current Costing Literature on Interventions to Reach Zero-Dose Children in Low- and Middle-Income Countries

A study in Vaccines analyzes the costs and effectiveness of interventions aimed at reaching zero-dose children—those who have not received any routine vaccinations—in low- and middle-income countries (LMICs). The research evaluates strategies such as mobile outreach, community engagement, and health system strengthening, highlighting their cost-effectiveness in improving immunisation coverage. The findings suggest that tailored, context-specific … Read More

Private sector engagement for immunisation programs: a pragmatic scoping review of 25 years of evidence on good practice in low-income and middle-income countries

A study in BMJ Global Health explores the role of private sector engagement in strengthening immunisation programs in low- and middle-income countries (LMICs). The research highlights that partnerships with private healthcare providers, pharmacies, and businesses can expand vaccine access, improve service delivery, and increase coverage. Key strategies include leveraging private sector infrastructure, integrating public-private data … Read More

Socioeconomic-related inequities in child immunisation: horizontal and vertical dimensions for policy insights

A study in Health Economics Review investigates the economic and equity impacts of expanding immunisation programs in low- and middle-income countries (LMICs), focusing on the cost-effectiveness of introducing new vaccines. The research highlights that while scaling up immunisation efforts requires significant investment, the long-term benefits—such as reduced disease burden, healthcare savings, and improved productivity—justify the … Read More